1 exciting growth stock to buy for the long run in June

Shares of Moderna have more than doubled since mid-November. Here’s why this writer thinks it’s now a stock to buy for his portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When looking for a stock to buy, it can often be best to start with one’s own portfolio. Are there any shares in there that I’d like to add to?

There are a handful, actually. But until recently, Moderna (NASDAQ: MRNA) wasn’t one of them. That’s because sales of the firm’s only product, the Spikevax Covid vaccine, have been declining rapidly as the pandemic fades in the rear-view mirror.

In 2022, the company generated nearly $19bn in sales. This year, it’s only expecting $4bn.

Should you invest £1,000 in Moderna right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Moderna made the list?

See the 6 stocks

However, 2024 might prove to be an inflection point for this digital biotech stock. Here’s why.

Created with Highcharts 11.4.3Moderna PriceZoom1M3M6MYTD1Y5Y10YALL11 Jun 201911 Jun 2024Zoom ▾Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '242020202020212021202220222023202320242024www.fool.co.uk

Two-product company

In late May, the company received approval for mRESVIA, a vaccine for respiratory syncytial virus (RSV). This causes mild, cold-like symptoms but can lead to serious respiratory illnesses, especially in infants and the elderly.

This was the first approved mRNA vaccine for a disease outside of Covid. But this isn’t the only RSV shot. GSK and Pfizer both had theirs approved 12 months ago.

However, Moderna’s vaccine is the only one to come in a pre-filled syringe. This compares favourably with the multi-step process of its competitors’ products.

Here’s what Moderna’s CFO James Mock said about these rival RSV jabs: “So you have to mix it and swirl it and then take a jab and measure it out. And so that is prone to error or breakage and that is cost.”

He believes that busy pharmacies and healthcare providers will buy in to its more efficient administration method. And despite being late to the party, he estimates that the firm has a good chance of capturing at least an equal share (33%) of this large market over time.

A risk to consider

Now, I should note that the firm is currently generating losses as it invests in its various programmes.

This isn’t a problem yet as it still had $12.2bn in cash and investments, as of 31 March. And the company expects to break even in 2026 through product launches and disciplined investment.

But investors will want to monitor how quickly this war chest starts to dwindle over the next couple of years. It always adds risk to the investment case when a firm is loss-making.

More positive news

Yesterday (10 June), the firm announced that its combined flu-Covid jab provoked a higher immune response when compared to separate shots (including its own Spikevax) in a late-stage trial.

If approved, this 2-in-1 jab could upend the global flu vaccine market. “This is a home run,” CEO Stéphane Bancel told Barron’s. “The whole field has been waiting for something like this.”

He estimates that the total addressable market could go up by three times compared to Covid alone.

Looking ahead, Moderna says sales from its collection of respiratory vaccines could be between $8bn-$15bn in 2027. So, the company may more than treble its sales over a three-year period.

By that point, we might also have approvals for one of its experimental mRNA cancer vaccines that are currently in phase 2 and 3 studies for several types of cancer.

There are also vaccine candidates for HIV, Zika and cytomegalovirus. The future suddenly looks very exciting. As a result, I’m going to add more shares to my portfolio for the long term.

AI Revolution Awaits: Uncover Top Stock Picks for Massive Potential Gains!

Buckle up because we're about to dive headfirst into the electrifying world of AI.

Imagine this: you make a single savvy investment in some cutting-edge technology, then kick back and watch as it revolutionises entire industries and potentially even lines your pockets.

If the mere thought of riding this AI wave excites you and the prospect of massive potential returns gets your pulse racing, then you’ve got to check out this Motley Fool Share Advisor report – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And here’s the kicker – we’re giving you an exclusive peek at ONE of these top AI stock picks, absolutely free! How’s that for a bit of brilliance?

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Moderna. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

This FTSE 250 share offers a juicy 9.8% yield. Will it last?

This well-known FTSE 250 share has a percentage dividend yield approaching double digits. Should Christopher Ruane add the income share…

Read more »

Investing Articles

Is a £333,000 portfolio enough to retire and live off passive income?

A third of a million pounds can generate a serious amount of passive income, but relying on this sum alone…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing For Beginners

Why FTSE 100 investors should pay attention to ‘Liberation Day’

Jon Smith explains why the upcoming tariff announcement from across the pond could have an impact on the FTSE 100,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s why Nvidia stock fell 13% in March

The Nvidia stock price rise was looking unstoppable. Should investors now be wondering if the same might be true of…

Read more »

US Stock

It’s ISA deadline week! Here’s my 3-step game plan

Jon Smith tries to calm the hype around the last minute ISA rush to buy stocks and explains why he's…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£10,000 invested in BAE Systems shares at Christmas is now worth…

BAE Systems shares have been surging in the FTSE 100 in 2025, driven higher by the wavering US commitment to…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »